Stock Chart
IBRX
Type: SELL wallstreet
Strike: $12
Premium: $2.95
Expiry: Aug 20, 2027
Target: $13
Score: -75
LEAPs are long-term options (1+ year) with less time decay.
Vol: Current volume vs 20-day average
vs SPY: Relative activity vs market
vs QQQ: Relative activity vs tech
Color Guide:
● Red (≥1.5x): High activity
● Yellow (≥1.2x): Above average
● Blue (≤0.7x): Low activity
Interpretation:
• vs SPY > 1: Stock-specific interest
• vs SPY < 1: Stock quiet vs market
Technical Chart
About IBRX - ImmunityBio, Inc. Common Stock
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two …
Key Statistics
More IBRX Analysis
This IBRX stock chart provides comprehensive technical analysis including candlestick patterns, volume profile analysis, and options open interest data. Track IBRX's price movements with trendlines, gamma walls, and key support/resistance levels.